Sooma Medical Awarded US Patent for Advanced Stimulation Electrode

HELSINKI, Jan. 11, 2019 /PRNewswire/ --ASoomaAMedical announces receipt of a U.S. patent for its new stimulation electrode. The electrode technology is essential for safe and effective delivery of allAneuromodulationAtherapies.The electrode technology developed byASoomaAR&D team dramatically reduces the resistance in the skin-electrode interfaceAwhen compared to competing solutions. Further benefits of the patentedAtechnology are faster patient preparation and superior accuracy in delivery of the stimulation dose.AThe hydrophilic properties of the material ensure stable contact for extended periods of time.AThis technology is the result of a long term research project with industrial and academic partners finally reaching product stage. The company strategy is to keep the focus of technological innovations where it matters most to the patient and the clinical user: ease of use and patient safety. Since the launch of the new electrode more than 1000 patients worldwide have received SoomaAtDCSAtreatment in more than 20.000 treatment sessions.AWith yet another patent secured in the IP portfolio,ASoomaAMedical strengthens its position as the leading provider of home-basedAneuromodulationAsolutions with a unique product portfolio.ASoomaAtDCSAis a therapy product using weak electrical stimulation (transcranialAdirect current stimulation,AtDCS) and is intended for the treatment of major depressive disorder (MDD), chronic pain andAfibromyalgia. The devices are used by professionals and patients in over 100 clinics worldwide.A[/u]A59% of patients suffering from major depression obtained a treatment response after only 3 weeks of treatment.ASoomaAMedical product portfolio also includes a digital platform for remote supervision of patient compliance, behavioral changes, and treatment outcome.ASoomaAMedical has obtained regulatory approvals for the product in the following markets: EU (ClassAIIa), Canada, Mexico, Singapore, Australia, Malaysia, Indonesia, and Turkey. In the U.S. the FDA limits the use of theAtDCSAfor investigationalAuse only. Sooma products are distributed in over 30 countries.AVideo about the use of the new electrode [u]CONTACTS:ATuomasANeuvonen, CEO Atel.A+358 10 328 9811REF:AU.S. patent 10,173,049Related Images
Sooma Medical Awarded US Patent for Advanced Stimulation Electrode
View original content to download multimedia:SOURCE Sooma Medical Ltd
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«     2020    »